1. Borgna-Pignatti C, Bertelli S. Morbidity and life expectancy in patients with thalassemia major and Intermedia. Eur J Clin Med Oncol. 2011;3(1):8–13.
2. Global Burden of Diseases (2015) Mortality and Causes of Death, Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2015;388(10053):1459–544.
3. Caro J, Huybrechts KF, Green TC. Estimates of the effect on hepatic iron of oral deferiprone compared with subcutaneous desferrioxamine for treatment of iron overload in thalassaemia major: a systematic review. BMC Blood Disord. 2002;2:4.
4. Modell B, Khan M, Darlinson M. Survival in beta-thalassaemia major in the UK: data from the UK Thalassaemia register. Lancet. 2000;355:2051–2.
5. DiPalma A, Vullo C, Zani B, et al. Psychosocial integration of adolescents and young adults with Thalassaemia major. Ann N Y Acad Sci. 1998;850:355–60.